{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:28:29Z","timestamp":1782286109474,"version":"3.54.5"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070019"],"award-info":[{"award-number":["82070019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.chest.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T02:14:00Z","timestamp":1659233640000},"page":"100-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD"],"prefix":"10.1016","volume":"163","author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9859","key":"10.1016\/j.chest.2022.07.015_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"9859","key":"10.1016\/j.chest.2022.07.015_bib3","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1164\/rccm.202005-1854OC","article-title":"Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review","volume":"203","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2022.07.015_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.chest.2022.07.015_bib6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9167","key":"10.1016\/j.chest.2022.07.015_bib8","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial","volume":"353","author":"Vestbo","year":"1999","journal-title":"Lancet"},{"issue":"7245","key":"10.1016\/j.chest.2022.07.015_bib9","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.chest.2022.07.015_bib10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study","volume":"166","author":"van der Valk","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2022.07.015_bib11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2022.07.015_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1183\/09031936.00128806","article-title":"Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD","volume":"29","author":"L\u00f6fdahl","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib16","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1378\/chest.06-3009","article-title":"The efficacy and safety of combination salmeterol (50 microg)\/fluticasone propionate (500 microg) inhalation twice daily via Accuhaler in Chinese patients with COPD","volume":"132","author":"Zheng","year":"2007","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2022.07.015_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2022.07.015_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1378\/chest.07-2138","article-title":"Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD","volume":"134","author":"Rabe","year":"2008","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2022.07.015_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir Med"},{"issue":"14","key":"10.1016\/j.chest.2022.07.015_bib20","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-9-73","article-title":"One-year treatment with mometasone furoate in chronic obstructive pulmonary disease","volume":"9","author":"Calverley","year":"2008","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2022.07.015_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"issue":"8","key":"10.1016\/j.chest.2022.07.015_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2022.07.015_bib25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.chest.2022.07.015_bib26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.rmed.2010.09.008","article-title":"Beclomethasone\/formoterol in the management of COPD: a randomised controlled trial","volume":"104","author":"Calverley","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2022.07.015_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","article-title":"Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study","volume":"106","author":"Sharafkhaneh","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2022.07.015_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/COPD.S27320","article-title":"Effects of mometasone furoate\/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week phase III trial in subjects with moderate-to-very severe COPD","volume":"7","author":"Doherty","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2022.07.015_bib29","first-page":"43","article-title":"Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week phase III trial","volume":"7","author":"Tashkin","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.chest.2022.07.015_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rmed.2012.12.014","article-title":"A\u00a0randomised trial of fluticasone furoate\/vilanterol (50\/25 \u03bcg; 100\/25 \u03bcg) on lung function in COPD","volume":"107","author":"Kerwin","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2022.07.015_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/resp.12090","article-title":"Budesonide\/formoterol via Turbuhaler\u00ae versus formoterol via Turbuhaler\u00ae in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results","volume":"18","author":"Fukuchi","year":"2013","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","article-title":"Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol\u2013fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study","volume":"1","author":"Vogelmeier","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2022.07.015_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","article-title":"Fluticasone furoate\/vilanterol (100\/25; 200\/25 \u03bcg) improves lung function in COPD: a randomised trial","volume":"107","author":"Martinez","year":"2013","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2022.07.015_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.chest.2022.07.015_bib35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12931-014-0105-2","article-title":"Fluticasone propionate\/salmeterol 250\/50 \u03bcg versus salmeterol 50 \u03bcg after chronic obstructive pulmonary disease exacerbation","volume":"15","author":"Ohar","year":"2014","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib37","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1183\/09031936.00126814","article-title":"INSTEAD: a randomised switch trial of indacaterol versus salmeterol\/fluticasone in moderate COPD","volume":"44","author":"Rossi","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib38","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.13-2859","article-title":"Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate\/vilanterol with tiotropium","volume":"146","author":"Pepin","year":"2014","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.chest.2022.07.015_bib39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2022.07.015_bib40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2015.1036016","article-title":"Efficacy and safety of fluticasone furoate\/vilanterol (50\/25 mcg; 100\/25 mcg; 200\/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"31","author":"Zheng","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.chest.2022.07.015_bib41","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","article-title":"Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations","volume":"109","author":"Donohue","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2022.07.015_bib42","first-page":"1015","article-title":"LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD","volume":"10","author":"Zhong","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2022.07.015_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","article-title":"Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial","volume":"15","author":"Singh","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"13","key":"10.1016\/j.chest.2022.07.015_bib44","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","article-title":"Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice","volume":"375","author":"Vestbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2022.07.015_bib45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1183\/13993003.00216-2016","article-title":"Efficacy and safety of aclidinium\/formoterol versus salmeterol\/fluticasone: a phase 3 COPD study","volume":"48","author":"Vogelmeier","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2022.07.015_bib46","first-page":"1","article-title":"Efficacy and safety of fluticasone furoate\/vilanterol or tiotropium in subjects with COPD at cardiovascular risk","volume":"11","author":"Covelli","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/resp.12646","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia","volume":"21","author":"Lee","year":"2016","journal-title":"Respirology"},{"issue":"10030","key":"10.1016\/j.chest.2022.07.015_bib48","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.chest.2022.07.015_bib49","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2022.07.015_bib50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/COPD.S95055","article-title":"The lung function profile of once-daily tiotropium and olodaterol via Respimat(\u00ae) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(\u00ae) (ENERGITO(\u00ae) study)","volume":"11","author":"Beeh","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2022.07.015_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.rmed.2016.12.001","article-title":"A\u00a0randomised, phase III trial of once-daily fluticasone furoate\/vilanterol 100\/25 \u03bcg versus once-daily vilanterol 25 \u03bcg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD","volume":"123","author":"Siler","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2022.07.015_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/COPD.S117373","article-title":"A\u00a0randomized trial of once-daily fluticasone furoate\/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD","volume":"12","author":"Bhatt","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2022.07.015_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2017.09.002","article-title":"Effect of budesonide\/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study","volume":"132","author":"Ferguson","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2022.07.015_bib54","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/COPD.S136527","article-title":"Fluticasone propionate\/formoterol for COPD management: a randomized controlled trial","volume":"12","author":"Papi","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10082","key":"10.1016\/j.chest.2022.07.015_bib55","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2022.07.015_bib56","doi-asserted-by":"crossref","first-page":"1801334","DOI":"10.1183\/13993003.01334-2018","article-title":"Budesonide\/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study","volume":"52","author":"Ferguson","year":"2018","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2022.07.015_bib57","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/resp.13374","article-title":"Efficacy and safety of the direct switch to indacaterol\/glycopyrronium from salmeterol\/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial","volume":"23","author":"Frith","year":"2018","journal-title":"Respirology"},{"issue":"10125","key":"10.1016\/j.chest.2022.07.015_bib58","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2022.07.015_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-Term Triple Therapy De-escalation to Indacaterol\/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2022.07.015_bib60","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-019-1126-7","article-title":"Bone and ocular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study","volume":"20","author":"Kerwin","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2022.07.015_bib62","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2147\/COPD.S220861","article-title":"Long-term safety and efficacy of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD","volume":"14","author":"Ichinose","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2022.07.015_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619853500","article-title":"The efficacy of adding budesonide\/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China","volume":"13","author":"Huang","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.chest.2022.07.015_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41533-021-00241-z","article-title":"Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy versus tiotropium monotherapy in patients with COPD","volume":"31","author":"Bansal","year":"2021","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.chest.2022.07.015_bib65","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2022.07.015_bib66","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.chest.2022.07.015_bib67","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"issue":"7650","key":"10.1016\/j.chest.2022.07.015_bib68","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"26","key":"10.1016\/j.chest.2022.07.015_bib69","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"147","key":"10.1016\/j.chest.2022.07.015_bib70","doi-asserted-by":"crossref","first-page":"170103","DOI":"10.1183\/16000617.0103-2017","article-title":"Exacerbations of COPD","volume":"27","author":"Viniol","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.chest.2022.07.015_bib71","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1183\/09031936.04.00121404","article-title":"Impact of preventing exacerbations on deterioration of health status in COPD","volume":"23","author":"Spencer","year":"2004","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.chest.2022.07.015_bib72","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1513\/pats.200701-024FM","article-title":"Inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"4","author":"Suissa","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.chest.2022.07.015_bib73","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","article-title":"Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease","volume":"198","author":"Rothnie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.07.015_bib74","doi-asserted-by":"crossref","first-page":"691621","DOI":"10.3389\/fphar.2021.691621","article-title":"Inhaled\u00a0corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled\u00a0trials","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.chest.2022.07.015_bib75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archinternmed.2008.550","article-title":"Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis","volume":"169","author":"Singh","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.chest.2022.07.015_bib76","first-page":"CD010115","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"2014","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.chest.2022.07.015_bib77","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/15412555.2015.1081162","article-title":"Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: systematic review and meta-analysis","volume":"13","author":"Festic","year":"2016","journal-title":"COPD"},{"issue":"9691","key":"10.1016\/j.chest.2022.07.015_bib78","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0140-6736(09)61250-2","article-title":"Budesonide and the risk of pneumonia: a meta-analysis of individual patient data","volume":"374","author":"Sin","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2022.07.015_bib79","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/15412555.2020.1787369","article-title":"Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis","volume":"17","author":"Zhang","year":"2020","journal-title":"COPD"},{"issue":"5","key":"10.1016\/j.chest.2022.07.015_bib80","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1513\/AnnalsATS.202002-096OC","article-title":"Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT","volume":"18","author":"Dransfield","year":"2021","journal-title":"Ann Am Thorac Soc"}],"updated-by":[{"DOI":"10.1016\/j.chest.2023.03.042","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000}},{"DOI":"10.1016\/j.chest.2025.04.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000}}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222013459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222013459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:04:45Z","timestamp":1762124685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222013459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0012369222013459"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.07.015","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}